12:00 AM
 | 
Sep 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PORxin: Phase I/II

A double-blind, placebo-controlled, dose-escalation Phase I/II trial in 40 patients with moderate to severe BPH showed that 4 ascending-doses of PRX302 delivered via transrectal injection were well tolerated at 3 months, with no bacteremia, sepsis or drug-related sexual function adverse events...

Read the full 182 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >